Cancer clinical trials in the region Auvergne-Rhône-Alpes
499 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Chronic myeloid leukemia (CML)
#NCT06514534
#2024-516049-38-00
Required disease stage
Chronic phase
Accelerated phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Excluded previous treatments
Systemic Treatment-Naive
Allosteric inhibitor
7 recruiting sites
Novartis
Phase 2
Stomach and esophageal cancer
#NCT06846346
#2025-520694-39-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
Claudin 18.2
HER2
MSI/dMMR
7 recruiting sites
UNICANCER
Phase 2
Lymphoma
#NCT06271057
#2023-506705-20-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Primary mediastinal lymphoma
Indolent transformed lymphoma
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07059845
#2025-521606-18-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III
Stage IV
Required number of previous lines of therapy for current stage of disease
None
1
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07059845
#2025-521606-18-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III
Stage IV
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07059845
#2025-521606-18-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III
Stage IV
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
Multiple myeloma
#NCT04935684
Required histologic types
B cell lymphoma
T cell lymphoma
Hodgkin lymphoma
CLL (Chronic Lymphocytic Leukemia)
Symptomatic multiple myeloma
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CHU de Clermont-Ferrand
Phase 2
Multiple myeloma
#NCT05572229
#2022-001594-31
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
17 recruiting sites
Hôpital universitaire de Lille
Phase 2
Lung cancer
#NCT06855771
#2024-519814-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2
Thyroid and adrenal gland cancer
#NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
14 recruiting sites
Centre Léon Bérard